Literature DB >> 17276141

Interferon-gamma gene+874T-A polymorphism is associated with tuberculosis and gamma interferon response.

Nilgün Sallakci1, Mesut Coskun, Zafer Berber, Fuat Gürkan, Halil Kocamaz, Gülnar Uysal, Sabin Bhuju, Ugur Yavuzer, Mahavir Singh, Olcay Yeğin.   

Abstract

Interferon-gamma is the most important cytokine in resistance to mycobacterial diseases and common variants of interferon-gamma gene could be related to tuberculosis susceptibility. We tested the hypothesis that the interferon-gamma+874T-A polymorphism is associated with tuberculosis disease, and affects the interferon-gamma response. We determined by pyrosequencing the distribution of the interferon-gamma+874T-A polymorphism in a Turkish population of 319 patients with pulmonary tuberculosis, 42 children with severe forms of tuberculosis and 115 healthy donors. We also analysed whether any correlation exists between this polymorphism and interferon-gamma response to Mycobacterium tuberculosis antigens by ELISPOT in 58 pulmonary tuberculosis cases, and the results were analysed according to the genotypes. We found that the minor allele (T) frequency was significantly lower in patients with pulmonary tuberculosis when compared to controls (P=0.024, OR=0.7), a similarly significant decrease in the frequency of TT genotype was observed in patients with pulmonary tuberculosis, compared to the control group (P=0.02, OR=0.49). IFN-gamma responses to PPD antigen in TT genotype was found to be significantly higher than the AA group (P>0.001). Non-parametric correlation analysis of ELISPOT data showed significant reverse correlation in PPD, CFP10 and ESAT6 values and IFN-gamma +874 genotypes. These results show that the IFN-gamma +874T-A polymorphism is related to the IFN-gamma response and the magnitude of the response decreases during transition from TT- to TA and to AA genotypes. Our data suggest that similar to various Caucasian populations, in a Turkish population the IFN-gamma+874 T-A polymorphism is also associated with tuberculosis disease and affects the magnitude of the IFN-gamma response.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17276141     DOI: 10.1016/j.tube.2006.10.002

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  22 in total

1.  Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial.

Authors:  Danyelle A Winchester; Cathee Till; Phyllis J Goodman; Catherine M Tangen; Regina M Santella; Teresa L Johnson-Pais; Robin J Leach; Jianfeng Xu; S Lilly Zheng; Ian M Thompson; M Scott Lucia; Scott M Lippman; Howard L Parnes; William B Isaacs; Angelo M De Marzo; Charles G Drake; Elizabeth A Platz
Journal:  Prostate       Date:  2017-03-20       Impact factor: 4.104

2.  Distinctive frequencies of +874T/A IFN-γ gene polymorphism in a healthy Serbian population.

Authors:  Dusan Popadic; Emina Savic; Zorica Spuran; Milos Markovic; Marija Mostarica Stojkovic; Zorica Ramic; Vera Pravica
Journal:  Clin Transl Sci       Date:  2012-10-17       Impact factor: 4.689

Review 3.  Association of polymorphism +874 A/T of interferon-γ and susceptibility to the development of tuberculosis: meta-analysis.

Authors:  A C de Albuquerque; L Q Rocha; A H de Morais Batista; A B Teixeira; D B Dos Santos; N A P Nogueira
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-06-09       Impact factor: 3.267

4.  IFNG +874 T>A single nucleotide polymorphism is associated with leprosy among Brazilians.

Authors:  C C Cardoso; A C Pereira; V N Brito-de-Souza; I M Dias-Baptista; V C Maniero; J Venturini; F R Vilani-Moreno; F C de Souza; M Ribeiro-Alves; E N Sarno; A G Pacheco; M O Moraes
Journal:  Hum Genet       Date:  2010-08-17       Impact factor: 4.132

5.  No Strong Relationship Between Components of the Lectin Pathway of Complement and Susceptibility to Pulmonary Tuberculosis.

Authors:  James D Chalmers; Misao Matsushita; David C Kilpatrick; Adam T Hill
Journal:  Inflammation       Date:  2015-08       Impact factor: 4.092

6.  IFNG +874T/A, IL10 -1082G/A and TNF -308G/A polymorphisms in association with tuberculosis susceptibility: a meta-analysis study.

Authors:  Antonio Guilherme Pacheco; Cynthia Chester Cardoso; Milton Ozório Moraes
Journal:  Hum Genet       Date:  2008-04-15       Impact factor: 4.132

7.  Role of IFN-gamma +874 T/A single nucleotide polymorphism in the tuberculosis outcome among Brazilians subjects.

Authors:  Lucia H L V Amim; Antonio G Pacheco; Joseane Fonseca-Costa; Carla S Loredo; Marcelo F Rabahi; Maria H Melo; Fernando C V Ribeiro; Fernanda C Q Mello; Martha M Oliveira; José R Lapa e Silva; Tom H Ottenhoff; Afrânio L Kritski; Adalberto R Santos
Journal:  Mol Biol Rep       Date:  2007-08-08       Impact factor: 2.316

8.  Common studied polymorphisms do not affect plasma cytokine levels upon endotoxin exposure in humans.

Authors:  S Taudorf; K S Krabbe; R M G Berg; K Møller; B K Pedersen; H Bruunsgaard
Journal:  Clin Exp Immunol       Date:  2008-02-25       Impact factor: 4.330

9.  Human atopic dermatitis complicated by eczema herpeticum is associated with abnormalities in IFN-γ response.

Authors:  Donald Y M Leung; Pei-Song Gao; Dmitry N Grigoryev; Nicholas M Rafaels; Joanne E Streib; Michael D Howell; Patricia A Taylor; Mark Boguniewicz; Jennifer Canniff; Brian Armstrong; Daniel J Zaccaro; Lynda C Schneider; Tissa R Hata; Jon M Hanifin; Lisa A Beck; Adriana Weinberg; Kathleen C Barnes
Journal:  J Allergy Clin Immunol       Date:  2011-04       Impact factor: 10.793

10.  Cytokine Polymorphisms, Their Influence and Levels in Brazilian Patients with Pulmonary Tuberculosis during Antituberculosis Treatment.

Authors:  Eliana Peresi; Larissa Ragozo Cardoso Oliveira; Weber Laurentino da Silva; Erika Alessandra Pellison Nunes da Costa; João Pessoa Araujo; Jairo Aparecido Ayres; Maria Rita Parise Fortes; Edward A Graviss; Ana Carla Pereira; Sueli Aparecida Calvi
Journal:  Tuberc Res Treat       Date:  2013-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.